Date | Product | Disease | Phase | Company | Therapeutic area |
---|---|---|---|---|---|
2012-02-07 | Bexsero® | meningococcal B diseases | Novartis (Switzerland) | Infectious diseases | |
2012-02-06 | Intuniv® (guanfacine) | attention deficit hyperactivity disorder (ADHD) in children and adolescents ages 6 to 17 | Shire (UK) | Mental diseases - CNS diseases | |
2012-02-05 | GSK2586184 (formerly GLPG0778) | systemic lupus erythematosus | 2 | GSK (UK) Galapagos (Belgium) | Autoimmune diseases |
2012-02-03 | GFT505 | NAFLD (non-alcoholic fatty liver disease) - NASH (non-alcoholic steatohepatitis) | 2 | Genfit (France) | Metabolic diseases - Liver diseases |
2012-02-02 | talactoferrin | severe sepsis | 2-3 | Agennix (Germany) | Infectious diseases |
2012-02-02 | Esmya® (ulipristal acetate) | pre-operative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age |
3 | Preglem (Switzerland) member of the Richter Group (Hungary) | Gynecology - Women's health |
2012-02-01 | Ixiaro®/Jespect® | Japanese encephalitis | 3 | Intercell (Austria) | Infectious diseases |
2012-01-31 | Vivitrol® (naltrexone for extended-release injectable suspension) | opioid dependence |
1 | Alkermes (Ireland - USA) | CNS diseases |
2012-01-30 | Varisolve® (polidocanol endovenous microfoam (PEM) | varicose veins | 3 | BTG International (UK) | Cardiovascular diseases |
2012-01-27 | AT9283 | acute lymphoblastic leukaemia |
Cancer Research UK (UK) | Cancer Oncology | |
2012-01-26 | Tysabri® (natalizumab) | secondary-progressive multiple sclerosis (SPMS) |
3b | BiogenIdec (USA) Elan (Ireland) | Autoimmune diseases - Neurodegenerative diseases |
2012-01-25 | RhuDex® | rheumatoid arthritis | formulation study | MediGene (Germany) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
2012-01-24 | Ruconest® (Rhucin® in non-European territories - conestat alfa) | acute angioedema attacks in patients with Hereditary Angioedema (HAE) | post-marketing study | Pharming (The Netherlands) | Rare diseases - Genetic diseases |
2012-01-23 | TASQ (tasquinimod) | chemorefractory metastatic castration-resistant prostate cancer (CRPC) |
1 | Active Biotech (Sweden) | Cancer - Oncology |
2012-01-18 | WX-554 | 1 | Wilex (Germany) | Cancer - Oncology | |
2012-01-18 | regorafenib (BAY 73-4506) | metastatic colorectal cancer |
3 | Bayer Healthcare (Germany) | Cancer - Oncology |
2012-01-18 | IFX-1 (monoclonal antibody inhibiting complement driven inflammation) | 1 | InflaRx (Germany) | ||
2012-01-17 | PEV7 therapeutic Candida vaccine | recurrent vulvovaginal candidiasis (RVVC) | 1 | Pevion Biotech (Switzerland) | Infectious diseases - Gynecology - Women's health |
2012-01-16 | Cogane® (PYM50028) | amyotrophic lateral sclerosis | preclinical | Phytopharm (UK) | Neurodegenerative diseases |
2012-01-12 | rucaparib (CO-338; formerly called AG-014699 or PF-01367338) | inherited breast and ovarian cancers | 2 | Cancer Research UK (UK) | Cancer - Oncology |